-
Huabei pharmaceutical's patent for two tip antitumor compounds will be approved soon
Time of Update: 2020-04-03
A patent applied for by Huabei Pharmaceutical Group new drug research and Development Co., Ltd., a subsidiary of Huabei pharmaceutical, with a shareholding of 97%, is recently authorized by the State
-
Guizhou bailing develops the ancestral secret recipe of diabetes or 100 million Buyouts
Time of Update: 2020-04-03
Guizhou bailing, which has been acting as the leader of Miao medicine, announced today that the company signed the Miao medicine cooperative development agreement with Yang Guoshun and Yang Ailong on
-
Clinical approval of three kinds of corticosteroids in Xianju pharmaceutical
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on May 29, the status of the 3.1-class chemical difacote and difacote tablets applied for clinical application of Xianju pharm
-
Clinical approval for the second harvest of Johnson & Johnson cagregyne
Time of Update: 2020-04-03
The processing status of jxhl13000468 was changed to CFDA approval on December 16, indicating that the acceptance will be approved clinically According to insight database, caglejing has made three cl
-
Shanghai Aike Baifa Biomedical Technology Co., Ltd. completed round a financing
Time of Update: 2020-04-03
Shanghai Aike Baifa Biomedical Technology Co., Ltd., a biomedical technology company specializing in the development of new drugs for respiratory virus infection and viral hepatitis, today announced t
-
Hengrui shr7390 tablet and Baiji Shenzhou bgb-3111 capsule were approved for clinical use
Time of Update: 2020-04-03
The clinical application of class 1.1 new drugs of shr7390 tablets entered CFDA drug review center on December 31, 2014, and took a special review channel Shr7390 is a MEK kinase inhibitor developed f
-
Baiyunshan announced the results of phase Ⅱ B clinical trial of therapeutic double plasmid HBV DNA vaccine project
Time of Update: 2020-04-03
On December 14, 2013, it was announced that the therapeutic double plasmid HBV DNA vaccine project invested by Guangzhou Baiyunshan Pharmaceutical Co., Ltd with a 60% interest and developed by the 458
-
New drugs for chronic hepatitis C in China enter phase III clinical practice
Time of Update: 2020-04-03
"China has the largest number of hepatitis patients in the world, with 93 million hepatitis B carriers, accounting for one third of the global total, while 45 million hepatitis C carriers account for
-
Tonghua Dongbao cooperates with Suzhou Zhonghe to develop GLP-1
Time of Update: 2020-04-03
Tonghua Dongbao signed a "technology development contract" with Suzhou Zhonghe Biomedical Technology Co., Ltd., which will entrust the latter with the research and development of GLP-1 fusion protein
-
Esomeprazole, a major new drug in Laimei pharmaceutical industry, obtained GMP certificate
Time of Update: 2020-04-03
In the evening of April 1, Laimei pharmaceutical announced that the company received the GMP certificate issued by Chongqing food and drug administration, including esomeprazole API and capsule produc
-
Flupentixol-t-melitracen tablets, a new antidepressant drug of hisilic, will be used for the first time in the field
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 15, six kinds of new antidepressant drug of Hisilicon, Flupentixol and melitracen tablets, entered the site for inspe
-
Application for registration of "paracetamol oral suspension" of 6 chemical generic drugs of Kangzhi Pharmaceutical Co., Ltd. has been accepted
Time of Update: 2020-04-03
Kangzhi pharmaceutical announced in the afternoon of February 21 that on February 19, 2014, the company received the notice of acceptance of drug registration application from the State Food and Drug
-
Haizheng pharmaceutical and celsion sign a memorandum of understanding to continue to promote thermodox
Time of Update: 2020-04-03
Haizheng pharmaceutical announced in the evening of July 19 that on July 19, the company signed a memorandum of understanding with celsion company of the United States to continue to promote the clini
-
Hengrui pharmaceutical 1.1 tumor drug cimetidine obtained clinical approval
Time of Update: 2020-04-03
According to the information on the website of the State Food and Drug Administration (CFDA) on May 14, the declared clinical status of the 1.1-type chemical raw materials and tablets of Hengrui pharm
-
Take stock of 88 listed drugs approved by CFDA in the first half of 2016
Time of Update: 2020-04-03
July 12), State Food and Drug Administration issued an announcement that in June 2016, the State Food and Drug Administration approved 5 drug listing applications, all of which are domestic chemicals
-
Clinical approval of fospropofol sodium dihydrate in synthetic pharmaceutical industry
Time of Update: 2020-04-03
Announcement No.: 2015-042 securities code: 832077 securities abbreviation: Synthetic Pharmaceutical sponsor securities firm: Guohai Securities Shaanxi Synthetic Pharmaceutical Co., Ltd announcement o
-
Yiteng pharmaceutical and Ablynx reached a cooperation agreement on the nanotherapy antibody alx-0141 for osteoporosis
Time of Update: 2020-04-03
On October 14, 2013, Yiteng pharmaceutical, a fast-growing professional pharmaceutical company in China, announced a cooperation with Ablynx pharmaceutical Yiteng pharmaceutical was authorized by Ably
-
Ibonatide, a new diabetes drug of Changshan pharmaceutical industry, is expected to obtain clinical approval in the second half of the year
Time of Update: 2020-04-03
Changshan pharmaceutical industry said in a conference call that the company's first class 1 new drug, ibuprofen, is expected to obtain the first phase of clinical trial approval and start clinical tr
-
Fuhong Hanlin, a subsidiary of Fosun Pharmaceutical, obtained the first clinical approval for monoclonal antibody drugs
Time of Update: 2020-04-03
On April 2, Fosun Pharmaceutical holding company Shanghai Fuhong Hanlin Biotechnology Co., Ltd (hereinafter referred to as "Fuhong Hanlin") formally received the approval document for clinical trial o
-
Hanyu Pharmaceutical Co., Ltd. will obtain the production approval this year
Time of Update: 2020-04-03
Hanyu pharmaceutical said at the 2013 performance presentation that the company's heavyweight new drug enkephalin will be approved this year Enkephalin injection has the effect of anti platelet aggreg
